Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (CC): Updated analysis of stage II disease from the AVANT phase III randomized trial by the GERCOR group

被引：0

作者：

De Gramont, A. ^{[1
]}

Henriques, J. ^{[2
]}

Baruch, B. ^{[3
,4
]}

Kim, T. W. ^{[5
]}

Martinez-Villacampa, M. ^{[6
]}

Gallego-Plazas, J. ^{[7
]}

Cervantes, A. ^{[8
]}

Shim, K. ^{[9
]}

Jonker, D. J. ^{[10
]}

Guerin-Meyer, V. ^{[11
]}

Mineur, L. ^{[12
]}

Banzi, M. ^{[13
]}

Dewdney, A. ^{[14
]}

Dejthevaporn, T. Sirisingha ^{[15
]}

Bloemendal, H. J. ^{[16
]}

Roth, A. D. ^{[17
]}

Thompson, P. ^{[18
]}

Moehler, M. ^{[19
]}

Aranda Aguilar, E. ^{[20
]}

Andre, T. ^{[21
]}

机构：

[1] Inst Hosp Franco Britannique, Dept Med Oncol, Levallois Perret, France

[2] Univ Hosp Besancon, INSERM, UMR 1098, Methodol & Qual Life Unit Oncol, Besancon, France

[3] Rabin Med Ctr, Davidoff Canc Ctr, Dept Oncol, Petah Tiqwa, Israel

[4] Sackler Sch Med, Tel Aviv, Israel

[5] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Oncol, Seoul, South Korea

[6] Inst Catala Oncol IDIBELL Hospitalet, Dept Med Oncol, Barcelona, Spain

[7] Gen Univ Elche Hosp, Dept Med Oncol, Elche, Spain

[8] Hosp Clin Univ Valencia, Med Oncol, Valencia, Spain

[9] Lakeridge Hlth RS McLaughlin Durham Reg Canc Ctr, Med Oncol, Oshawa, ON, Canada

[10] Univ Ottawa, Ottawa Hosp Res Inst, Div Med Oncol, Dept Med, Ottawa, ON, Canada

[11] Inst Cancerol Ouest Paul Papin, Dept Gastroenterol & Hepatol, Angers, France

[12] Inst St Catherine, Radiotherapy & Oncol GI & Liver, Avignon, France

[13] Azienda Osped Arcispedale Santa Maria Nuova IRCCS, Oncol Unit, Reggio Emilia, Italy

[14] Weston Pk Hosp, Canc Res Ctr, Dept Oncol, Sheffield, S Yorkshire, England

[15] Ramathibodi Hosp, Med Oncol, Bangkok, Thailand

[16] Meander Med Ctr, Dept Internal Med Med Oncol, Amersfoort, Netherlands

[17] HUG, Dept Oncol, Digest Tumour Unit, Geneva, Switzerland

[18] Auckland City Hosp, Dept Med Oncol, Auckland, New Zealand

[19] Univ Med Mainz, Dept Med Oncol, Mainz, Germany

[20] Univ Hosp Reina Sofia, Dept Med Oncol, Cordoba, Spain

[21] Hop St Antoine, Dept Med Oncol, Paris, France

来源：

ANNALS OF ONCOLOGY | 2019年 / 30卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

553P

引用

页数：1

共 50 条

[1] Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial
de Gramont, Aimery
Van Cutsem, Eric
Schmoll, Hans-Joachim
Tabernero, Josep
Clarke, Stephen
Moore, Malcolm J.
Cunningham, David
Cartwright, Thomas H.
Hecht, J. Randolph
Rivera, Fernando
Im, Seock-Ah
Bodoky, Gyoergy
Salazar, Ramon
Maindrault-Goebel, Frederique
Shacham-Shmueli, Einat
Bajetta, Emilio
Makrutzki, Martina
Shang, Aijing
Andre, Thierry
Hoff, Paulo M.
LANCET ONCOLOGY, 2012, 13 (12): : 1225 - 1233
[2] Bevacizumab as adjuvant treatment for colon cancer: Updated results from the AVANT phase III study by the GERCOR group
Andre, T.
Vernerey, D.
Im, S. -A.
Bodoky, G. M.
Buzzoni, R.
Reingold, S.
Rivera, F.
McKendrick, J.
Scheithauer, W.
Geva, R.
Fountzilas, G.
Yong, W. P.
Isaacs, R.
Osterlund, P.
Liang, J. -T.
Creemers, G. -J.
Van Cutsem, E.
Cunningham, D.
Tabernero, J.
De Gramont, A.
ANNALS OF ONCOLOGY, 2019, 30
[3] Bevacizumab as adjuvant treatment of colon cancer: updated results from the S-AVANT phase III study by the GERCOR Group
Andre, T.
Vernerey, D.
Im, S. A.
Bodoky, G.
Buzzoni, R.
Reingold, S.
Rivera, F.
McKendrick, J.
Scheithauer, W.
Ravit, G.
Fountzilas, G.
Yong, W. P.
Isaacs, R.
Osterlund, P.
Liang, J. T.
Creemers, G. J.
Rakez, M.
Van Cutsem, E.
Cunningham, D.
Tabernero, J.
de Gramont, A.
ANNALS OF ONCOLOGY, 2020, 31 (02) : 246 - 256
[4] Association of Bevacizumab Plus Oxaliplatin-Based Chemotherapy With Disease-Free Survival and Overall Survival in Patients With Stage II Colon Cancer A Secondary Analysis of the AVANT Trial
Chibaudel, Benoist
Henriques, Julie
Rakez, Manel
Brenner, Baruch
Kim, Tae Won
Martinez-Villacampa, Mercedes
Gallego-Plazas, Javier
Cervantes, Andres
Shim, Katharine
Jonker, Derek
Guerin-Meyer, Veronique
Mineur, Laurent
Banzi, Chiara
Dewdney, Alice
Dejthevaporn, Thitiya
Bloemendal, Haiko J.
Roth, Arnaud
Moehler, Markus
Aranda, Enrique
Van Cutsem, Eric
Tabernero, Josep
Schmoll, Hans-Joachim
Hoff, Paulo M.
Andre, Thierry
de Gramont, Aimery
JAMA NETWORK OPEN, 2020, 3 (10) : E2020425
[5] Effect of Delay in Adjuvant Oxaliplatin-Based Chemotherapy for Stage III Colon Cancer
Peixoto, Renata D'Alpino
Kumar, Aalok
Speers, Caroline
Renouf, Daniel
Kennecke, Hagen F.
Lim, Howard J.
Cheung, Winson Y.
Melosky, Barbara
Gill, Sharlene
CLINICAL COLORECTAL CANCER, 2015, 14 (01) : 25 - 30
[6] Impact of delay in adjuvant oxaliplatin-based chemotherapy for stage III colon cancer.
Peixoto, Renata D'Alpino
Kumar, Aalok
Speers, Caroline
Renouf, Daniel John
Kennecke, Hagen F.
Lim, Howard John
Cheung, Winson Y.
Melosky, Barbara L.
Gill, Sharlene
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[7] Duration of oxaliplatin-based adjuvant chemotherapy in patients with Stage III or high-risk Stage II resected colon cancer
Moretto, Roberto
Falcone, Alfredo
Cremolini, Chiara
INTERNATIONAL JOURNAL OF CANCER, 2020, 146 (09) : 2652 - 2654
[8] Association of Bevacizumab Plus Oxaliplatin-Based Chemotherapy With Disease-Free Survival and Overall Survival in Patients With Stage II Colon Cancer: A Secondary Analysis of the AVANT Trial (vol 3, e2020425, 2020)
Chibaudel, B.
Henriques, J.
Rakez, M.
JAMA NETWORK OPEN, 2021, 4 (02)
[9] Oxaliplatin-based adjuvant chemotherapy duration (3 versus 6 months) for high-risk stage II colon cancer: the randomized phase III ACHIEVE-2 trial
Yamazaki, K.
Yamanaka, T.
Shiozawa, M.
Manaka, D.
Kotaka, M.
Gamoh, M.
Shiomi, A.
Makiyama, A.
Munemoto, Y.
Rikiyama, T.
Fukunaga, M.
Ueki, T.
Shitara, K.
Shinkai, H.
Tanida, N.
Oki, E.
Sunami, E.
Ohtsu, A.
Maehara, Y.
Yoshino, T.
ANNALS OF ONCOLOGY, 2021, 32 (01) : 77 - 84
[10] Prognostic value of methylator phenotype in stage III colon cancer treated with oxaliplatin-based adjuvant chemotherapy
Gallois, C.
Taieb, J.
Le Corre, D.
Le Malicot, K.
Tabernero, J.
Mulot, C.
Seitz, J-F.
Aparicio, T.
Folprecht, G.
Lepage, C.
Mini, E.
Van Laethem, J-L.
Emile, J. F.
Laurent-Puig, P.
ANNALS OF ONCOLOGY, 2017, 28

← 1 2 3 4 5 →